023 Numbness, Tingling and Treatment: Making Sense of Neuropathy
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
Dr Jam & Sally unpack what neuropathy is, why it happens in myeloma treatment, and how patients can recognise, prevent and manage it to protect their quality of life.
📌Key Takeaways:
- Know the signs early – tingling, numbness or pain shouldn’t be ignored; speak up before symptoms worsen.
- Treatment can be adjusted – modern dosing and combinations make neuropathy less common and more manageable.
- You don’t have to live with it – there are effective ways to ease nerve pain and protect your long-term wellbeing.
For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/
This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS
Dr. Jam Kothari
Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.